Generating Cost Reductions for U.S. Medicaid Model (GENEROUS)

Analysis updated November 9, 2026

Strategic questions for your team

What is our current Medicaid net drug spend baseline, and against which specific high-cost single source or innovator multiple source CODs in our formulary are participating manufacturers (including AstraZeneca, Pfizer, and EMD Serono) offering MFN pricing — and can we quantify the potential GNUP-driven savings using the formula Supplemental Rebate = WAC – (GNUP + URA), given that Medicaid net drug spending nationally reached $60 billion in 2024, a $10 billion increase from 2022?
Do we have, or can we obtain by August 31, 2026, all required legal authorities — specifically a CMS-approved State Plan Amendment (SPA) authorizing supplemental rebate agreements for both FFS and managed care claims — and if new state legislation or regulations are required, is our anticipated timeline compatible with the state PA execution deadline of August 31, 2026?
Are our existing supplemental rebate agreements (SRAs) and multistate purchasing pool memberships compatible with GENEROUS participation, given that the model prohibits states from negotiating any additional supplemental rebates on CODs for which MFN pricing is accessed, and requires states to modify or terminate existing SRAs upon implementing a model SRA for a model drug?
Can our Medicaid managed care alignment infrastructure — contracts, memoranda of understanding, and MCO communications — be updated to uniformly apply CMS-negotiated Key Terms (including prior authorization, step therapy, quantity limits, and PDL placement) across all managed care organizations and FFS delivery systems before we begin model implementation, given that CMS requires documented proof of alignment prior to any model SRA taking effect?
What is our PDL update cycle timeline relative to GENEROUS pricing windows — specifically, can we operationally implement MFN prices between January 1 and December 31 of each model year, given that state PA execution is due August 31, 2026, MFN pricing data for model year 2027 will be shared by states no later than June 30, 2026, and each GNUP is guaranteed for at least 12 months from the SRA effective date?
What are the quarterly invoicing and data management burdens we must absorb, given that states must invoice manufacturers for supplemental rebates within 60 days of the end of each calendar quarter, manufacturers have 37 days to pay before interest accrues, rebate calculations must be maintained at the NDC-9 level, and CMS will audit both state and manufacturer data through an independent contractor — and do our MMIS and pharmacy claims systems have the technical capability to support these requirements?
For drug classes where multiple manufacturers may offer MFN pricing, how will we structure our PDL decision-making to comply with the model's non-disfavoring rule — which prohibits states from favoring one participating manufacturer over another within the same drug class as long as all products are operating within their approved FDA labels — while still achieving optimal net cost outcomes across our Medicaid population?
What is our risk tolerance for CMS's retained right to modify any model policy or parameter annually or more frequently, terminate our state Participation Agreement for poor performance or non-compliance, and potentially waive or modify other CMMI model requirements for GENEROUS participants — and how does this policy modification risk interact with our existing multi-year drug contracting and managed care rate-setting cycles through December 31, 2030?
How will GENEROUS participation affect our 340B program operations, given the RFA's explicit confirmation that GENEROUS supplemental rebates do not alter Medicaid Best Price calculations and therefore do not affect 340B ceiling prices — and have we verified with our 340B covered entities that the standardized coverage criteria negotiated by CMS and manufacturers will not restrict access to drugs currently available under 340B pricing?
Have we assessed which specific CODs offered by confirmed participating manufacturers (AstraZeneca, Pfizer, EMD Serono) represent our highest-volume or highest-cost Medicaid utilization at the NDC-9 level, and does the MFN country basket benchmark — the second-lowest GDP-per-capita-adjusted net price across the UK, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland — yield a GNUP below our current net cost after existing statutory rebates (23.1% of AMP basic rebate plus any inflation rebates) and any current supplemental rebates?
Given that all 50 states have applied for the GENEROUS model and CMS projects $64.3 billion in savings, what is our state's proportional share of projected savings, and how should we communicate realistic benefit estimates to our legislature and governor's office while accounting for the fact that many model details remain unknown and actual savings will depend on which specific drugs and manufacturers ultimately participate in our state's SRAs?
Has CMS identified any drug classes or specific manufacturers — such as Novo Nordisk and its GLP-1 or insulin products — that may be structured as exceptions or receive preferential treatment under the GENEROUS model's MFN framework, and if so, how does any such carve-out affect our state's projected savings and our formulary strategy for those high-utilization therapeutic categories?
Given that every state has now applied and the program is moving toward simultaneous implementation, what operational capacity constraints does our Medicaid agency face in executing SPAs, updating managed care contracts, and retooling MMIS systems on a compressed timeline shared by all 50 states — and have we secured sufficient legal, actuarial, and IT resources to meet the August 31, 2026 PA execution deadline without depending on vendor or federal support that may be stretched thin across all state applicants?

Traps and concerns

Retroactive Rebate Liability Gap
Manufacturers that execute Participation Agreements before June 30, 2026, must provide MFN rebates retroactive to January 1, 2026, for states that participate in the model. However, states cannot execute their own Participation Agreements until August 31, 2026, and may not finalize individual SRAs until well after that date. This creates a reconciliation exposure window of up to 8-11 months in which rebate calculations are based on international pricing data reported within 30 days of the manufacturer PA — data that may not yet have been audited by the CMS contractor. States that fail to properly document units dispensed during this retroactive window risk invoicing errors that, under the GNUP formula (Supplemental Rebate = WAC – [GNUP + URA]), could produce underpayment or overpayment disputes. With Medicaid net drug spending at $60 billion in 2024, even a 1% reconciliation error on a large-volume COD portfolio could represent tens of millions of dollars in disputed rebate liability across dozens of states simultaneously.
State Plan Amendment Bottleneck
Every participating state must obtain CMS approval of a State Plan Amendment (SPA) authorizing entry into supplemental rebate agreements before executing any model SRA. States that have not previously secured this authority — and the RFA explicitly requires applicants to disclose whether a SPA is needed — face a compressed approval timeline: state RFAs are due July 31, 2026, and Participation Agreements must be signed by August 31, 2026. The SPA approval process at CMCS routinely takes 90-180 days under normal circumstances. States that also require new state legislation or regulatory changes face even longer timelines — the RFA requires disclosure of these situations but offers no guaranteed accommodation. States that miss the August 31, 2026 PA deadline are locked out of participation except at CMS discretion, meaning they forfeit access to MFN pricing and the associated FMAP-shared supplemental rebates for the entire model year, with no defined re-entry pathway guaranteed. With all 50 states now confirmed as applicants (per AJMC, September 2026), CMCS faces an unprecedented simultaneous SPA review workload that could further extend normal approval timelines and create bottlenecks that disproportionately disadvantage states with more complex legislative authorization requirements.
Managed Care Alignment Compliance Failure
The model requires that MFN pricing Key Terms and standardized access policies apply equally to both FFS Medicaid and Medicaid managed care beneficiaries. States must contractually obligate all applicable MCOs, prepaid inpatient health plans, and prepaid ambulatory health plans to adopt the CMS-manufacturer negotiated coverage criteria — including prior authorization, step therapy, and quantity limits — and must submit documentation of this alignment to CMS before implementation. Given that the majority of Medicaid beneficiaries nationally are enrolled in managed care, failure to achieve alignment creates a two-tiered access system that violates model terms and could trigger PA termination by CMS. States that use P&T committees or DUR boards (flagged as a concern in the LOI) to set clinical criteria face a structural conflict: the model requires adoption of CMS-negotiated criteria, potentially bypassing established state formulary governance processes and creating legal exposure under state administrative procedure laws.
International Price Data Integrity and Gaming Risk
The GNUP — the financial cornerstone of the entire model — is derived from the second-lowest country-specific manufacturer-reported net price across a basket of 8 countries (UK, France, Germany, Italy, Canada, Japan, Denmark, Switzerland), adjusted for GDP per capita purchasing power parity at the NDC-9 level. Critically, manufacturers self-report this international pricing data; CMS audits it only through a contractor engaged after the fact. For Year 1, data covers October 1, 2024 through September 30, 2025, and must be submitted within 30 days of PA execution. Manufacturers have strong financial incentives to report higher net international prices (after rebates and discounts) to minimize the supplemental rebate owed to states. Dosage form mismatches between countries — explicitly acknowledged in the RFA, which notes that a UK 20mg cartridge may be matched to a U.S. 20mg pen — create additional pricing ambiguity that sophisticated manufacturers could exploit. A 10-cent-per-unit overstatement of the GNUP on a high-volume drug dispensed to millions of Medicaid beneficiaries quarterly could eliminate tens of millions of dollars in intended savings before the audit contractor flags the discrepancy.
PDL Timing Misalignment Undermines Savings Capture
States operate PDL update cycles on varying annual timelines — many states update PDLs 6-12 months in advance using P&T committee reviews, purchasing pool bids, and managed care contract negotiations. For model Year 2 (2027), MFN prices are calculated from a reporting period of April 1, 2025 to March 31, 2026, data must reach states by June 30, 2026, and states implement at any point during calendar year 2027. However, a state that locks its PDL in January 2027 based on pricing data available in June 2026 cannot easily incorporate an enhanced MFN price that becomes available mid-year. While states may elect to adopt enhanced MFN prices mid-cycle, doing so requires modifying or terminating existing SRAs for the same drug — a contractual action that may trigger dispute resolution under existing supplemental rebate agreements with non-model manufacturers. States participating in multi-state supplemental rebate purchasing pools (flagged as a concern in the LOI) face the additional risk that accessing MFN pricing for a drug eliminates their ability to negotiate any further supplemental rebates on that drug, potentially leaving them worse off than their pool arrangements if the MFN GNUP exceeds what the pool could have negotiated.
Same-Class Multi-Manufacturer Non-Disfavor Mandate
When multiple manufacturers offer MFN pricing for drugs within the same therapeutic class, the model prohibits states from disfavoring any participating manufacturer's product relative to another — as long as all products are operating within their FDA-approved labels. This non-disfavor rule directly conflicts with standard PDL management strategy, in which states use preferred/non-preferred tiering and step therapy to concentrate volume on a single product in exchange for deeper rebates. Under GENEROUS, a state that accepts MFN pricing from two competing manufacturers in, for example, the GLP-1 or PCSK9 inhibitor class cannot use formulary positioning to drive volume to the product with the lower net cost. The model bars additional supplemental rebate negotiations for any COD on which the state is accessing MFN pricing, eliminating the leverage states normally use to improve net pricing through preferred placement. This structural constraint could reduce total rebate capture compared to a state's pre-model supplemental rebate strategy, particularly for drug classes where current pool-negotiated rebates exceed the MFN-derived GNUP.
Voluntary Manufacturer Exit Creates Mid-Model Coverage Gaps
GENEROUS is fully voluntary for manufacturers, and a participating manufacturer may terminate its Participation Agreement — subject to PA terms — at any point during the five-year model period ending December 31, 2030. If a manufacturer exits mid-model, states that have restructured their PDLs, terminated prior SRAs with the manufacturer, and aligned MCO contracts around the model's standardized coverage criteria face an immediate operational crisis: they must rapidly re-establish supplemental rebate agreements outside the model, re-engage P&T processes, and renegotiate managed care contracts — all without the MFN pricing advantage. The model's prohibition on negotiating additional supplemental rebates while accessing MFN pricing means that states will have allowed prior non-model SRAs to lapse or be modified; those contractual relationships cannot be reinstated instantly. For high-cost specialty drugs where the manufacturer was one of a small number of MDRP participants, a manufacturer exit could result in months during which a state pays full net statutory rebate pricing (basic rebate of 23.1% of AMP plus inflation rebate, without supplemental rebates) while scrambling to rebuild its rebate position.
Manufacturer-Specific Exemptions Undermine Projected Savings and Coverage Uniformity
Reporting by STAT News (September 2026) indicates that the Trump administration's GENEROUS model may include arrangements that constitute significant financial wins for specific manufacturers — with Novo Nordisk cited as a prominent example — raising concerns that individual manufacturer deal terms or carve-outs could exempt high-cost, high-volume drug classes from full MFN pricing obligations. If the COD list or GNUP methodology is structured in a way that effectively excludes or discounts GLP-1 drugs (among the highest-cost classes in Medicaid), the CMS-projected $64.3 billion in model savings (per AJMC, September 2026) could be materially overstated. States that have structured their PDL strategy and MCO contract terms around anticipated MFN pricing for GLP-1 or other high-utilization specialty classes would face a gap between projected and realized savings. Because the model's savings projections are the primary basis on which states are making administrative investment decisions — including SPA submissions, SRA restructuring, and MCO contract modifications — any systematic manufacturer-specific exemptions not disclosed in the RFA create both a financial planning risk and a potential legal challenge ground if states argue they participated based on materially incomplete information.
Implementation Detail Gaps Expose All 50 States to Simultaneous Operational Risk
Despite all 50 states submitting applications (confirmed by CMS and AJMC, September 2026), STAT News reporting from September 2026 notes that many critical implementation details remain unknown at the time of universal state enrollment. This is an unprecedented operational risk profile: unlike prior voluntary CMMI models where a subset of states participated and CMS could manage implementation challenges sequentially, GENEROUS requires CMS to simultaneously execute Participation Agreements, review SPAs, validate manufacturer price data submissions, onboard audit contractors, and support MCO alignment documentation for all 50 states and the District of Columbia at once. CMS and CMMI do not have established infrastructure for this scale of concurrent implementation. If the model's operational guidance, standardized SRA templates, or audit contractor capacity are not finalized before states begin executing agreements, the resulting implementation ambiguity will be exploited differently across states — creating inconsistent COD coverage policies, uneven retroactive rebate enforcement, and a patchwork of MCO alignment compliance that undermines the model's core premise of uniform MFN access for all Medicaid beneficiaries nationally.